Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye diseases
Biotech
Opthea scraps wet AMD program after eye drug loses to Lucentis
Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to can the entire wet AMD program.
James Waldron
Mar 31, 2025 6:55am
NIH creates eye drops that protect mice from vision loss
Mar 25, 2025 3:10pm
Eye disease biotech looks to clinical trials with $93M series B
Mar 25, 2025 8:00am
Cell therapy biotech Aurion joins IPO surge
Jan 27, 2025 2:42pm
4DMT restructures pipeline, extending cash runway through 2028
Jan 10, 2025 2:00pm
Oculis peptidomimetic helps protect eyes from nerve inflammation
Jan 6, 2025 5:27am
